The UK Medicines and Healthcare products Regulatory Agency (MHRA) and US Food and Drug Administration (FDA) have announced a new liaison programme.
The agencies share that the roles aim to enhance day-to-day collaboration, support scientific exchange and enable faster, more coordinated approaches to emerging regulatory challenges and decisions.
The initiative formalises and deepens co-operation between the two agencies across key focus areas, including innovative medicines, medical devices and emerging technologies such as AI, according to both parties.
According to the MHRA and FDA, both agencies will maintain full regulatory independence, while enabling closer alignment and collaboration where it delivers a clear public health benefit.
Grace Graham, FDA deputy commissioner, said, “American patients and innovators benefit when regulators collaborate, as aligning on regulatory science can speed access to medical products and reduce time to markets both here and in the UK. We’re excited to launch this new initiative that will enhance institutional knowledge within the FDA and MHRA, improving the global oversight of drugs, biologics and medical devices as we look to secure supply chains and ensure appropriate standards for clinical research.”